

DAFTAR PUSTAKA

- Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK, et al. Oncogenic PI3K mutations are as common as *AKT1* and *SMO* mutations in meningioma. *Neuro Oncol.* 2016 May;18(5):649–55. doi:[10.1093/neuonc/nov316](https://doi.org/10.1093/neuonc/nov316)
- Abikenari M, Regev A, Himic V, Choi J, Jeyaretna S, Fountain DM, et al. The hormonal nexus in PIK3CA-mutated meningiomas: implications for targeted therapy and clinical trial design. *J Neurooncol.* 2025 Sep;174(2):329–40. doi:[10.1007/s11060-025-05082-1](https://doi.org/10.1007/s11060-025-05082-1)
- Adekanmbi A, Youngblood MW, Karras CL, Oyetunji EA, Kalapurakal J, Horbinski CM, et al. Clinical Management of Supratentorial Non-Skull Base Meningiomas. *Cancers.* 2022 Nov 29;14(23):5887. doi:[10.3390/cancers14235887](https://doi.org/10.3390/cancers14235887)
- Al-Mefty O, Topsakal C, Pravdenkova S, Sawyer JR, Harrison MJ. Radiation-induced meningiomas: clinical, pathological, cytogenetic, and cytogenetic characteristics. *Journal of Neurosurgery.* 2004 Jun;100(6):1002–13. doi:[10.3171/jns.2004.100.6.1002](https://doi.org/10.3171/jns.2004.100.6.1002)
- Arinda L, Susanti R, Indra S. Angiomatous type meningioma in a male patient. *Jurnal Kesehatan Andalas.* 2019 Jan 24;8(2S):82. doi:[10.25077/jka.v8i2S.962](https://doi.org/10.25077/jka.v8i2S.962)
- Arnli MB, Backer-Grøndahl T, Ytterhus B, Granli US, Lydersen S, Gulati S, et al. Expression and clinical value of EGFR in human meningiomas. *PeerJ.* 2017 Mar 29;5:e3140. doi:[10.7717/peerj.3140](https://doi.org/10.7717/peerj.3140)
- Bernatz S, Monden D, Gessler F, Radic T, Hattingen E, Senft C, et al. Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients. *J Mol Histol.* 2021 Apr;52(2):233–43. doi:[10.1007/s10735-020-09940-2](https://doi.org/10.1007/s10735-020-09940-2)
- Bi WL, Prabhu VC, Dunn IF. High-grade meningiomas: biology and implications. *Neurosurgical Focus.* 2018 Apr;44(4):E2. doi:[10.3171/2017.12.FOCUS17756](https://doi.org/10.3171/2017.12.FOCUS17756)
- Blankenstein MA, Verheijen FM, Jacobs JM, Donker TH, Van Duijnhoven MWF, Thijssen JH. Occurrence, regulation, and significance of progesterone receptors in human meningioma. *Steroids.* 2000;65(10–11):795–800. doi:[10.1016/s0039-128x\(00\)00193-8](https://doi.org/10.1016/s0039-128x(00)00193-8)
- Cahill MA, Jazayeri JA, Catalano SM, Toyokuni S, Kovacevic Z, Richardson DR. The emerging role of progesterone receptor membrane component 1

- (PGRMC1) in cancer biology. *Biochim Biophys Acta Rev Cancer*. 2016;1866(2):339–49. doi: 10.1016/j.bbcan.2016.07.004
- Cardis E, Deltour I, Vrijheid M, Combalot E, Moissonnier M, Tardy H, et al. Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study. *Int J Epidemiol*. 2010;39(3):675–94. doi: 10.1093/ije/dyq079
- Carroll RS, Glowacka D, Dashner K, Black PM. Progesterone receptor expression in meningiomas. *Cancer Res*. 1993;53(6):1312–6. PMID: 8443810
- Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Özduman K, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. *Science*. 2013;339(6123):1077–80. doi: 10.1126/science.1233009
- Claus EB, Calvocoressi L, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M. Family and personal medical history and risk of meningioma. *J Neurosurg*. 2011;115(6):1072–7. doi: 10.3171/2011.6.JNS11129
- Corinna C, Zygourakis RM. *Neuro-Oncology*. In: Bernstein M, Berger M, editors. Georg Thieme Verlag; 2015. doi: 10.1055/b-002-98007
- Coy S, Rashid R, Stemmer-Rachamimov A, Santagata S. An update on the CNS manifestations of neurofibromatosis type 2. *Acta Neuropathol*. 2020;139(4):643–65. doi: 10.1007/s00401-019-02029-5
- Damayanti AA, Kalanjati VP, Wahyuhadi J. Korelasi Usia dan Jenis Kelamin dengan Angka Kejadian Meningioma. *AKSONA*. 2022;1(1):34–8. doi: 10.20473/aksona.v1i1.99
- Lekanne Deprez RH, Bianchi AB, Groen NA, Seizinger BR, Hagemijer A, van Drunen E, et al. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas. *Am J Hum Genet*. 1994;54(6):1022–9. PMID: 7911002
- Desai P, Patel D. A study of meningioma in relation to age, sex, site, symptoms, and computerized tomography scan features. *Int J Med Sci Public Health*. 2016;5(2):331–5. doi: 10.5455/ijmsph.2016.06102015124
- Domingues P, González-Tablas M, Otero Á, Pascual D, Ruiz L, Miranda D, et al. Genetic/molecular alterations of meningiomas and the signaling pathways targeted. *Oncotarget*. 2015;6(13):10671–88. doi: 10.18632/oncotarget.3870
- Evans DG, Watson C, King A, Wallace AJ, Baser ME. Multiple meningiomas: differential involvement of the NF2 gene in children and adults. *J Med Genet*. 2005;42(1):45–8. doi: 10.1136/jmg.2004.023705
- Ferluga S, Baiz D, Hilton DA, Adams CL, Ercolano E, Dunn J, et al. Constitutive activation of the EGFR-STAT1 axis increases proliferation of

- meningioma tumor cells. *Neurooncol Adv.* 2020;2(1):vdad008. doi: 10.1093/noajnl/vdad008
- Flint-Richter P, Mandelzweig L, Oberman B, Sadetzki S. Possible interaction between ionizing radiation, smoking, and gender in the causation of meningioma. *Neuro Oncol.* 2011;13(3):345–52. doi: 10.1093/neuonc/noq201
- Gousias K, Schramm J, Simon M. The Simpson grading revisited: aggressive surgery and its place in modern meningioma management. *J Neurosurg.* 2016;125(3):551–60. doi: 10.3171/2015.9.JNS15754
- Graillon T, Boissonneau S, Appay R, Boucekine M, Peyrière H, Meyer M, et al. Meningiomas in patients with long-term exposition to progestins: characteristics and outcome. *Neurochirurgie.* 2021;67(6):556–63. doi: 10.1016/j.neuchi.2021.04.018
- Greenberg MS. *Handbook of Neurosurgery*. 7th ed. New York: Thieme Medical Publishers; 2010. Chapter 21, p. 613–25.
- Hage M, Plesa O, Lemaire I, Raffin Sanson ML. Estrogen and progesterone therapy and meningiomas. *Endocrinology.* 2022;163(2):bqab259. doi: 10.1210/endocr/bqab259
- Harter PN, Braun Y, Plate KH. Classification of meningiomas—advances and controversies. *Chin Clin Oncol.* 2017;6(2):1–8. doi: 10.21037/cco.2017.05.02
- He W, Liu Z, Jie D, Tang L, Teng H, Xu J. Management of skull-base meningiomas with extracranial extensions: clinical features, radiological findings, surgical strategies, and long-term outcomes. *Front Neurol.* 2022;13:855973. doi: 10.3389/fneur.2022.855973
- Ichwan S, Santoso F, Aman RA, Tandian D, Fachniadin A, Nugroho SW. Estrogen and progesterone in meningioma: bridging the gap of knowledge. *Neurol Asia.* 2023;28(1):1–11. doi: 10.54029/2023wxj
- Iqbal M, Hussein L, Mahdi. Immunohistochemistry study of expression of TNF- α , TRAF-1, and TRAF-2 in patients suffer from ulcerative colitis. *Int J Adv Res.* 2015;3:604–20.
- Jang SH, Kim KJ, Oh MH, Lee JH, Lee HJ, Cho HD, et al. Clinicopathological significance of elevated PIK3CA expression in gastric cancer. *J Gastric Cancer.* 2016;16(2):85–92. doi: 10.5230/jgc.2016.16.2.85
- Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, et al. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. *J Clin Oncol.* 2015;33(34):4093–8. doi: 10.1200/JCO.2015.61.6490
- Johann DJ, Shin IJ, Roberge A, Laun S, Peterson EA, Liu M, et al. Effect of antigen retrieval on genomic DNA from immunodissected samples. *J*

Histochem Cytochem. 2022;70(9):643–58. doi: 10.1369/00221554221124163

Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. *Neuro Oncol.* 2014;16(6):829–40. doi: 10.1093/neuonc/not330

Kazemi NJ, Kaye AH. *Meningiomas*. London: Springer; 2009. doi: 10.1007/978-1-84628-784-8

Kementerian Kesehatan Republik Indonesia. *Pedoman Nasional Pelayanan Kedokteran Tumor Otak*. Jakarta: Kemenkes RI; 2017. Available from: <http://kanker.kemkes.go.id/guidelines/PNPKOtak.pdf>

Kim SW, Roh J, Park CS. Immunohistochemistry for pathologists: protocols, pitfalls, and tips. *J Pathol Transl Med.* 2016;50(6):411–8. doi: 10.4132/jptm.2016.08.08

Klaeboe L, Lonn S, Scheie D, Auvinen A, Christensen HC, Feychting M, et al. Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968–1997. *Int J Cancer.* 2005;117(6):996–1001. doi: 10.1002/ijc.21255

Kuroi Y, Matsumoto K, Shibuya M, Kasuya H. Progesterone receptor is responsible for benign biology of skull base meningioma. *World Neurosurg.* 2018;118:e918–24. doi: 10.1016/j.wneu.2018.07.100

Lee YS, Lee YS. Molecular characteristics of meningiomas. *J Pathol Transl Med.* 2020;54(1):45–63. doi: 10.4132/jptm.2019.11.05

Li Y, Yang SR, Chen YB, Adusumilli P, Bialik A, Bodd F, et al. Dual NF2-YAP/TAZ immunohistochemistry is a reliable marker for the detection of NF2 alterations in diffuse pleural mesothelioma. *Res Sq [Preprint]*. 2022. doi: 10.21203/rs.3.rs-1720495/v1

Link MJ, Perry A. Meningioma tumorigenesis: an overview of etiologic factors. In: *Meningiomas: Diagnosis, Treatment and Outcome*. 2009. p. 137–46.

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro Oncol.* 2021;23(8):1231–51. doi: 10.1093/neuonc/noab106

Magill ST, Young JS, Chae R, Aghi MK, Theodosopoulos P, McDermott MW. Relationship between tumor location, size, and WHO grade in meningioma. *Neurosurg Focus.* 2018;44(4):E4. doi: 10.3171/2018.1.FOCUS17752

Maiuri F, Mariniello G, de Divitiis O, Esposito F, Guadagno E, Teodonno G, et al. Progesterone receptor expression in meningiomas: pathological and

- prognostic implications. *Front Oncol.* 2021;11:611218. doi: 10.3389/fonc.2021.611218
- Mansouri A, Klironomos G, Taslimi S, Kilian A, Gentili F, Khan OH, et al. Surgically resected skull base meningiomas demonstrate a divergent postoperative recurrence pattern compared with non-skull base meningiomas. *J Neurosurg.* 2016;125(2):431–40. doi: 10.3171/2015.7.JNS15546
- Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E, et al. Meningioma. *Crit Rev Oncol Hematol.* 2008;67(2):153–71. doi: 10.1016/j.critrevonc.2008.01.010
- Mawrin C, Chung C, Preusser M. Biology and clinical management challenges in meningioma. *Am Soc Clin Oncol Educ Book.* 2015;35:e106–15. doi: 10.14694/edbook.am.2015.35.e106
- Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. *J Neurooncol.* 2010;99(3):379–91. doi: 10.1007/s11060-010-0342-2
- Meling TR, Da-Broi M, Scheie D, Helseth E. Meningiomas: skull base versus non-skull base. *Neurosurg Rev.* 2019;42(1):163–73. doi: 10.1007/s10143-018-0976-7
- Mishra-Gorur K, Barak T, Kaulen LD, Henegariu O, Jin SC, Aguilera SM, et al. Pleiotropic role of TRAF7 in skull-base meningiomas and congenital heart disease. *Proc Natl Acad Sci USA.* 2023;120(16):e2214997120. doi: 10.1073/pnas.2214997120
- Nanda A, Bir S, Maiti T, Konar S, Missios S, Guthikonda B. Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization Grade I meningioma. *J Neurosurg.* 2017;126(1):201–11. doi: 10.3171/2016.1.JNS151842
- Nazem AA, Ruzevick J, Ferreira MJ Jr. Advances in meningioma genomics, proteomics, and epigenetics: insights into biomarker identification and targeted therapies. *Oncotarget.* 2020;11(49):4544–53. doi: 10.18632/oncotarget.27841
- Ogasawara C, Philbrick BD, Adamson DC. Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions. *Biomedicines.* 2021;9(3):319. doi: 10.3390/biomedicines9030319
- Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. *Neuro Oncol.* 2015;17 Suppl 4:iv1–62. doi: 10.1093/neuonc/nov189

- Patel B, Desai R, Pugazenthi S, Butt OH, Huang J, Kim AH. Identification and management of aggressive meningiomas. *Front Oncol*. 2022;12:851758. doi: 10.3389/fonc.2022.851758
- Pawloski JA, Fadel HA, Huang YW, Lee IY. Genomic biomarkers of meningioma: a focused review. *Int J Mol Sci*. 2021;22(19):10222. doi: 10.3390/ijms221910222
- Peyre M, Gaillard S, de Marcellus C, Giry M, Bielle F, Villa C, et al. Progesterone-associated shift of meningioma mutational landscape. *Ann Oncol*. 2018;29(3):681–6. doi: 10.1093/annonc/mdx763
- Phillips LE, Koepsell TD, van Belle G, Kukull WA, Gehrels J, Longstreth WT. History of head trauma and risk of intracranial meningioma: population-based case-control study. *Neurology*. 2002;58(12):1849–52. doi: 10.1212/WNL.58.12.1849
- Preusser M, Brastianos PK, Mawrin C. Advances in meningioma genetics: novel therapeutic opportunities. *Nat Rev Neurol*. 2018;14(2):106–15. doi: 10.1038/nrneurol.2017.168
- Preusser M, Hassler M, Birner P, Rudas M, Acker T, Plate KH, et al. Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. *Clin Neuropathol*. 2012;31(5):352–60. doi: 10.5414/NP300488
- Rao RD. Oncology: an evidence-based approach [book review]. *Mayo Clin Proc*. 2006;81(5):706. doi: 10.4065/81.5.706-d
- Riemenschneider MJ, Perry A, Reifenberger G. Histological classification and molecular genetics of meningiomas. *Lancet Neurol*. 2006;5(12):1045–54. doi: 10.1016/S1474-4422(06)70625-1
- Rockhill J, Mrugala M, Chamberlain MC. Intracranial meningiomas: an overview of diagnosis and treatment. *Neurosurg Focus*. 2007;23(4):E1. doi: 10.3171/FOC-07/10/E1
- Rodríguez-Hernández LA, Uribe-Pacheco R, Mondragon-Soto M, Alvaro-Heredia J, Reyes-Moreno I, Montano-Tello H, et al. Assessing the malignancy risk of a meningioma by its location. *Cureus*. 2022;14(11):e31213. doi: 10.7759/cureus.31213
- Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. *J Neurosurg*. 2015;122(1):4–23. doi: 10.3171/2014.7.JNS131644
- Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, et al. Evidence for the complete inactivation of the NF2 gene in the majority of

- sporadic meningiomas. *Nat Genet.* 1994;6(2):180–4. doi: 10.1038/ng0294-180
- Saloner D, Uzelac A, Hetts S, Martin A, Dillon W. Modern meningioma imaging techniques. *J Neurooncol.* 2010;99(3):333–40. doi: 10.1007/s11060-010-0367-6
- Scarpin KM, Graham JD, Mote PA, Clarke CL. Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. *Nucl Recept Signal.* 2009;7:e009. doi: 10.1621/nrs.07009
- Shibuya M. Pathology and molecular genetics of meningioma: recent advances. *Neurol Med Chir (Tokyo).* 2015;55(1):14–27. doi: 10.2176/nmc.ra.2014-0233
- Shin HK, Park JH, Cho YH, Kim YH, Hong SH, Kim JH, et al. Risk factors for high-grade meningioma in brain and spine: systematic review and meta-analysis. *World Neurosurg.* 2021;151:e718–30. doi: 10.1016/j.wneu.2021.04.138
- Spangle JM, Roberts TM, Zhao JJ. The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. *Biochim Biophys Acta Rev Cancer.* 2017;1868(1):123–31. doi: 10.1016/j.bbcan.2017.03.002
- Spiegel-Kreinecker S, Lötsch D, Neumayer K, Kastler L, Gojo J, Pirker C, et al. Prognostic quality of activating TERT promoter mutations in meningioma: interaction with the tumor's mutational repertoire and cell immortalization in meningioma. *Neuro Oncol.* 2018;20(12):1584–93. doi: 10.1093/neuonc/noy104
- Suppiah S, Nassiri F, Bi WL, Dunn IF, Hanemann CO, Horbinski CM, et al. Molecular and translational advances in meningiomas. *Neuro Oncol.* 2019;21(Suppl 1):i4–17. doi: 10.1093/neuonc/noy178
- Tilak M, Holborn J, New LA, Lalonde J, Jones N. Receptor tyrosine kinase signaling and targeting in glioblastoma multiforme. *Int J Mol Sci.* 2021;22(4):1831. doi: 10.3390/ijms22041831
- Tokita MJ, Chen C, Chitayat D, Macnamara E, Rosenfeld JA, Hanchard N, et al. De novo missense variants in TRAF7 cause developmental delay, congenital anomalies, and dysmorphic features. *Am J Hum Genet.* 2018;103(1):154–62. doi: 10.1016/j.ajhg.2018.06.005
- Torp SH, Solheim O, Skjulsvik AJ. The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know—a minireview. *Acta Neurochir (Wien).* 2022;164(9):2453–64. doi: 10.1007/s00701-022-05301-y
- US National Library of Medicine. ClinicalTrials.gov [Internet]. NCT02523014: Mifepristone in Treating Patients With Recurrent or Refractory

- Meningioma. 2021 [cited 2024]. Available from: <https://clinicaltrials.gov/ct2/show/NCT02523014>
- Wahyuhadi J, Heryani D, Basuki H. Risk of meningioma associated with exposure of hormonal contraception: a case control study. *Maj Obstet Ginekol*. 2018;26(1):36–41. doi: 10.20473/mog.V26I12018.36-41
- Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. *J Neurooncol*. 2010;99(3):307–14. doi: 10.1007/s11060-010-0386-3
- Wigertz A, Lönn S, Mathiesen T, Ahlbom A, Hall P, Feychting M; Swedish INTERPHONE Study Group. Risk of brain tumors associated with exposure to exogenous female sex hormones. *Am J Epidemiol*. 2006;164(7):629–36. doi: 10.1093/aje/kwj254
- Yamaoka T, Kusumoto S, Ando K, Ohba M, Ohmori T. Receptor tyrosine kinase-targeted cancer therapy. *Int J Mol Sci*. 2018;19(11):3491. doi: 10.3390/ijms19113491
- Yamashima T. Human meninges: anatomy and its role in meningioma pathogenesis. In: *Meningiomas*. London: Springer; 2009. p. 15–24. doi: 10.1007/978-1-84628-784-8_3
- Youngblood MW, Duran D, Montejó JD, Li C, Omay SB, Özduman K, et al. Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. *J Neurosurg*. 2020;133(5):1345–54. doi: 10.3171/2019.8.JNS191266
- Yu T, Cao J, Alaa Eddine M, Moustafa M, Mock A, Erku C, et al. Receptor-tyrosine kinase inhibitor ponatinib inhibits meningioma growth in vitro and in vivo. *Cancers (Basel)*. 2021;13(23):5898. doi: 10.3390/cancers13235898
- Yuzawa S, Nishihara H, Yamaguchi S, Mohri H, Wang L, Kimura T, et al. Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system. *Mod Pathol*. 2016;29(7):708–16. doi: 10.1038/modpathol.2016.81
- Zadeh G, Karimi S, Aldape KD. PIK3CA mutations in meningioma. *Neuro Oncol*. 2016;18(5):603–4. doi: 10.1093/neuonc/now029
- Zhao AY, Youngblood MW, Erson-Omay EZ, Moliterno J, Gunel M. The genomic landscape of meningiomas. In: *Meningiomas*. Cham: Springer International Publishing; 2020. p. 35–55. doi: 10.1007/978-3-030-59558-6_4
- Zhou P, Ma W, Yin S, Li Y, Jiang S. Three risk factors for WHO grade II and III meningiomas: a study of 1737 cases from a single center. *Neurol India*. 2013;61(1):40–5. doi: 10.4103/0028-3886.107928

Zotti T, Scudiero I, Vito P, Stilo R. The emerging role of TRAF7 in tumor development. *J Cell Physiol.* 2017;232(6):1233–8. doi: 10.1002/jcp.25676

